
MEDIA RELEASE

Teva launches AJOVY® for the treatment of migraine with the YpsoMate® autoinjector from Ypsomed

Burgdorf, 31.03.2020, 7.00 a.m. – Teva Pharmaceutical Industries Ltd. (Teva), a global leader in generic medicines with innovative treatments in select areas, including central nervous system, pain and respiratory, launches its drug product AJOVY® in the pre-filled YpsoMate® 2.25 autoinjector from Ypsomed. AJOVY® is used for the preventive treatment of migraine in adults. The collaboration with Teva marks the first commercial market entry of Ypsomed's larger 2.25 ml autoinjector YpsoMate® 2.25.

Teva has announced the launch of AJOVY® in an autoinjector device for the German market in March 2020. AJOVY® (fremanezumab-vfrm), a humanised monoclonal antibody, is the first and only anti-CGRP treatment for the prevention of migraine with monthly and quarterly dosing options. According to the World Health Organisation, at least one in seven adults is affected by migraine worldwide. To date, Teva has marketed AJOVY® in a standard syringe. With the launch of the drug in an autoinjector, Teva now offers AJOVY® in a format, which is more convenient for patients.

The YpsoMate® 2.25 auto-injector is based on the same platform as the YpsoMate® with 1.0 ml fill volume, but is assembled with a syringe with 2.25 ml fill volume. Due to the higher fill volume, the YpsoMate® 2.25 is also suitable for drugs that need to be injected less frequently but in higher volumes. Ypsomed manufactures its YpsoMate® 2.25 on a fully automated production line at its Solothurn site in Switzerland.

"For us, the cooperation with Teva is yet another important milestone for our YpsoMate® autoinjector platforms. It is not only the second realised YpsoMate® project with Teva, but also the first commercial market launch for the YpsoMate® 2.25 large volume autoinjector. We see a growing need for injection devices for home use to increase quality of life for patients," comments Ulrike Bauer, Senior Vice President Ypsomed Delivery Systems.

For further information, please contact Thomas Kutt, Head of Investor Relations at Ypsomed Holding AG, at the telephone number +41 34 424 35 55 or by e-mail (thomas.kutt@ypsomed.com).

About the Ypsomed Group

The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years' experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife™ Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs almost 1 700 employees. Additional information is available under www.ypsomed.com.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. Teva delivers high-quality generic products and medicines in nearly every therapeutic area to address unmet patient needs. Teva has an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale. Teva strives to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, they employ 43 000 professionals, committed to improving the lives of millions of patients. Learn more at www.tevapharm.com.